U.S. GOP lawmakers are pushing for changes to how Trump’s FDA handles clinical trial diversity, arguing that enrollments should better match the demographics of the patients who will use the drugs. The push comes amid broader federal moves related to DEI language on agency sites following the Trump administration’s early actions. Supporters of trial diversity say the issue is not about hiring or communications but about representativeness and evidence quality. Regulatory attention to enrollment composition could affect trial design requirements and, in turn, the operational planning of multi-site studies seeking eventual FDA approvals.